Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	31.19	52.89	76.33	109.11	112.58	85.21
Short-Term Investments	-	-	-	-	33.82	41.7
Cash & Short-Term Investments	31.19	52.89	76.33	109.11	146.4	126.91
Cash Growth	-50.90%	-30.71%	-30.04%	-25.47%	15.36%	54.68%
Accounts Receivable	24.45	49.39	49.15	-	-	-
Other Receivables	2.46	3.09	1.55	1.08	2.64	6.18
Receivables	26.91	52.48	50.7	1.08	2.64	6.18
Prepaid Expenses	1.3	1.91	4.18	3.38	8.83	6.06
Total Current Assets	59.4	107.28	131.21	113.57	157.87	139.15
Property, Plant & Equipment	2.56	3.11	4.16	5.49	7.56	8.78
Long-Term Accounts Receivable	-	-	46.59	-	-	-
Other Long-Term Assets	0.15	0.15	0.44	5.74	5.64	5.52
Total Assets	62.12	110.54	182.39	124.8	171.07	153.45
Accounts Payable	0.78	7.31	1.38	0.62	1.1	1.16
Accrued Expenses	6.64	17.27	6.56	8.53	14.35	12.24
Current Portion of Leases	1.84	1.75	1.72	1.69	1.36	0.95
Current Income Taxes Payable	0.16	0.17	0.39	-	-	-
Current Unearned Revenue	5.43	22.12	27.11	10.37	1.86	-
Other Current Liabilities	0.08	0.46	-	0.45	-	-
Total Current Liabilities	14.95	49.07	37.15	21.65	18.67	14.34
Long-Term Debt	-	-	-	-	48.41	-
Long-Term Leases	1.77	2.55	3.83	4.96	5.97	6.89
Long-Term Unearned Revenue	12.58	12.8	34.43	22.17	8.79	-
Other Long-Term Liabilities	-	-	0.09	0.1	0.94	0.18
Total Liabilities	29.29	64.42	75.5	48.87	82.78	21.41
Common Stock	0.06	0.06	0.05	0.05	0.03	0.03
Additional Paid-In Capital	507.98	505.71	497.91	489.76	455.72	409.72
Retained Earnings	-475.2	-459.64	-391.07	-413.88	-367.46	-277.71
Comprehensive Income & Other	-	-	-	-	-0	-0.01
Total Common Equity	32.83	46.12	106.89	75.93	88.29	132.04
Shareholders' Equity	32.83	46.12	106.89	75.93	88.29	132.04
Total Liabilities & Equity	62.12	110.54	182.39	124.8	171.07	153.45
Total Debt	3.62	4.3	5.54	6.65	55.75	7.84
Net Cash (Debt)	27.58	48.59	70.79	102.46	90.65	119.07
Net Cash Growth	-52.93%	-31.36%	-30.91%	13.02%	-23.86%	55.64%
Net Cash Per Share	0.50	0.90	1.34	2.73	2.93	5.32
Filing Date Shares Outstanding	56.28	55.9	53.87	52.57	32.76	29.5
Total Common Shares Outstanding	56.19	54.59	53	52.46	32.39	29.26
Working Capital	44.46	58.2	94.06	91.92	139.2	124.8
Book Value Per Share	0.58	0.84	2.02	1.45	2.73	4.51
Tangible Book Value	32.83	46.12	106.89	75.93	88.29	132.04
Tangible Book Value Per Share	0.58	0.84	2.02	1.45	2.73	4.51
Machinery	-	1.55	1.55	1.55	1.76	1.76
Construction In Progress	-	-	-	-	-	0.04
Leasehold Improvements	-	1.64	1.64	1.64	1.64	1.64

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q